A Phase 2 interventional study of GenSci048 and Placebo in Endometriosis-related Pain, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Endometriosis with a site in China — 16 open to participants now, 17 under way, 2 of them phase 3. Endometriosis · China.
Among the 47 studies in Endometriosis with a site in China, this one is the 12th largest by planned enrollment of the 28 interventional ones that give a count, is one of 8 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 13 of the 16 other live ones, and was the 35th registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →16 of the 47 studies in Endometriosis with a site in China are open now. Recruiting first, the newest first:
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18–45 · Women only
Catherin Zhang · Sites in China
Ages 18–75 · Women only
Obstetrics & Gynecology Hospital of Fudan University · Sites in China
Ages 18–55 · Women only
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18–50 · Women only
Li Li · Sites in China
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 6 · Phase 4 3
First in 2008; this study’s year is marked. 8 started in 2025.
This study's planned enrollment of 200 is above the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 161 across the 28 interventional studies, 402 across the 19 observational. Of the 16 that completed or were terminated, 3 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 47 have an industry lead sponsor. The 10 most frequent:
Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.
Changchun GeneScience Pharmaceutical Co., Ltd. has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Endometriosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
| NCT06266897Zhujiang HospitalA Study on the Correlation Between Endometriosis and Intra-tissue Microbiota | 2026-12 |
| NCT07014761Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe Influence of Central Sensitization in Endometriosis Disease | 2027-03-31 |
| NCT07755956Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis | 2027-03-31 |
| NCT06584760The Fourth Affiliated Hospital of Zhejiang University School of MedicineResearch on the Impact of Chronic Pelvic Pain on Endometriosis | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 47 studies in Endometriosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GenSci048 subcutaneously (SC) every 4 weeks.
Drug: GenSci048
Administered SC every 4 weeks.
Drug: Placebo
Administered SC.
Administered SC.
Change of dysmenorrhea (DYS) measured by Numeric Rating Scale (NRS)
The NRS for overall endometriosis-associated pain ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: baseline, week 24
Change of non-menstrual pelvic pain (NMPP) measured by Numeric Rating Scale (NRS)
The NRS for overall endometriosis-associated pain ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: baseline, week 24
Change of DYS, NMPP, and dyspareunia (DYSP) measured by Numeric Rating Scale (NRS). The NRS for overall endometriosis-associated pain ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: 52 weeks
Permitted rescue medication use.
Time frame: 52 weeks
Patient Global Impression of Change, Patient Global Impression of Change (minimum 1, maximum 7, higher score mean a worse outcome).
Time frame: Week 12、Week 24、Week 52
Adverse Event
Time frame: up to approximately 56 weeks
Started May 2025 (actual). Primary completion is estimated for May 2028, 35 months after the start.
Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's planned 35 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GENSCI048
Changchun GeneScience Pharmaceutical Co., Ltd. →